Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRIT Capital Partners Regulatory News (RCP)

Share Price Information for RIT Capital Partners (RCP)

Share Price is delayed by 15 minutes
Get Live Data
2,320.00    -10.00 (-0.43%)
Bid:
2,320.00
Ask:
2,325.00
Spread: 5.00 (0.216%)
Market Cap: £3.15b
RCP Live PriceLast checked at - London Stock Exchange

Intraday RIT Capital Partners Share Chart

Net Asset Value(s)

17 Feb 2026 07:00

RNS Number : 2279T
RIT Capital Partners PLC
17 February 2026
 

RIT Capital Partners PLC (LEI: P31Q1NLTW35JJGHA4667)

17 February 2026

January 2026 Net Asset Value (NAV)

RIT Capital Partners plc's ("RITs") unaudited diluted NAV as at 31 January 2026 (with debt at fair value) was 2,958p per £1 ordinary share (31 December 2025: 2,921p1), +1.3% for the month.

Global equities rose in January, supported by improving economic growth and emerging markets led gains. In the United States, resilient economic indicators broadened a public equities rally, with SMID-caps outperforming and market leadership rotating toward cyclical and defensive sectors. European and Asian equities also advanced.

In currency markets, the US dollar weakened, supporting risk appetite outside the United States. Commodity prices surged, led by energy, while positive momentum in precious metals was supported by dollar weakness and ongoing macroeconomic uncertainty.

Against this market backdrop, our portfolio delivered a solid performance during the month, led by Quoted Equities and Uncorrelated Strategies. 

Performance highlights

·

Quoted Equities contributed positively to NAV, led by strong performance from our emerging markets and commodities-related holdings.

·

Performance from Private Investments was flat in January while we await Q4 2025 valuations from our fund partners. As at 31 January, over 99% of the funds portfolio is held at 30 September 2025 reported valuations, with the remaining balance at 30 June 2025.

·

Uncorrelated Strategies, which acts as a steady diversifier of returns, contributed positively, led by gold and credit.

·

Currencies detracted from our NAV, primarily due to strengthening of sterling against the US dollar, leading to a negative translation effect for our global portfolio.

·

We continued our ongoing share buyback programme, repurchasing £6.9 million or approximately 309,000 shares in January, adding an estimated +5bps accretion to NAV.

 

1 As is customary at this point in our year-end process, the preliminary December NAV and associated performance numbers for 2025 are estimates, and subject to potential adjustment and audit. Changes made to the December 2025 NAV could impact January's opening NAV and therefore January's performance. The 2025 Annual Report and Accounts are expected to be finalised and published by early March.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVQQLFFQLLZBBL
Date   Source Headline
4th Feb 20259:18 amRNSHolding(s) in Company
4th Feb 20257:00 amRNSTransaction in Own Shares
3rd Feb 20252:23 pmRNSTotal Voting Rights
31st Jan 20257:00 amRNSTransaction in Own Shares
28th Jan 20257:00 amRNSTransaction in Own Shares
23rd Jan 20257:00 amRNSTransaction in Own Shares
17th Jan 20255:13 pmRNSDirector/PDMR Shareholding
8th Jan 20257:00 amRNSTransaction in Own Shares
2nd Jan 20257:00 amRNSTransaction in Own Shares
2nd Jan 20257:00 amRNSShare Buyback Management
2nd Jan 20257:00 amRNSTotal Voting Rights
31st Dec 20247:00 amRNSTransaction in Own Shares
30th Dec 20247:00 amRNSTransaction in Own Shares
27th Dec 20247:00 amRNSTransaction in Own Shares
24th Dec 20247:00 amRNSTransaction in Own Shares
23rd Dec 20247:00 amRNSTransaction in Own Shares
20th Dec 20247:00 amRNSTransaction in Own Shares
19th Dec 20247:00 amRNSTransaction in Own Shares
18th Dec 20247:00 amRNSNet Asset Value(s)
17th Dec 20247:00 amRNSTransaction in Own Shares
16th Dec 20247:00 amRNSDirector/PDMR Shareholding
16th Dec 20247:00 amRNSTransaction in Own Shares
13th Dec 20247:00 amRNSTransaction in Own Shares
12th Dec 20247:00 amRNSTransaction in Own Shares
11th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
6th Dec 20247:00 amRNSTransaction in Own Shares
5th Dec 20247:00 amRNSTransaction in Own Shares
4th Dec 20247:00 amRNSTransaction in Own Shares
3rd Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 202411:57 amRNSTotal Voting Rights
2nd Dec 20247:00 amRNSTransaction in Own Shares
29th Nov 20247:00 amRNSTransaction in Own Shares
28th Nov 20247:00 amRNSTransaction in Own Shares
27th Nov 20247:00 amRNSTransaction in Own Shares
26th Nov 20247:00 amRNSTransaction in Own Shares
25th Nov 20247:00 amRNSTransaction in Own Shares
22nd Nov 20247:00 amRNSTransaction in Own Shares
21st Nov 20247:00 amRNSTransaction in Own Shares
20th Nov 20247:00 amRNSTransaction in Own Shares
19th Nov 20247:00 amRNSNet Asset Value(s)
18th Nov 20247:00 amRNSTransaction in Own Shares
13th Nov 202411:20 amRNSComposition of Conflicts Committee
13th Nov 20247:00 amRNSTransaction in Own Shares
12th Nov 20247:00 amRNSTransaction in Own Shares
7th Nov 20247:00 amRNSTransaction in Own Shares
6th Nov 20247:00 amRNSTransaction in Own Shares
5th Nov 20247:00 amRNSTransaction in Own Shares
4th Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 202412:14 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.